Northvane

How it works

What is lipoprotein apheresis, and who is it actually for?

Lipoprotein apheresis passes separated plasma through columns that trap LDL cholesterol and Lp(a), then returns it to the body. It is a second-line treatment for familial hypercholesterolemia that stays severe despite diet and maximum drug therapy, with FDA indications defined by LDL levels. Unlike therapeutic plasma exchange, it does not discard the patient's plasma.

Nov 18, 20268 min read

An empty two-lane country highway stretching through open farmland in soft early morning light, with mist lingering over the fields.
Illustration created with AI for this article. It does not show a real clinic or patient.

Lipoprotein apheresis is a repeated filtering treatment that removes LDL cholesterol and lipoprotein(a), or Lp(a), from the blood and returns the rest. It is mainly for people with familial hypercholesterolemia (FH) whose LDL stays very high despite diet and maximum drug therapy. Unlike the plasma exchange and INUSpheresis sold for longevity or detox, it has an FDA-approved device with defined indications and written Medicare coverage criteria.

What is lipoprotein apheresis, and what does it remove?

Lipoprotein apheresis is a nonsurgical treatment that separates the plasma (the liquid part of blood), filters LDL cholesterol and Lp(a) out of it, and returns the blood to the body. The Family Heart Foundation describes it as a two- to three-hour procedure in which the person is connected to a machine that filters their blood.

One established system is the Liposorber LA-15, made by Kaneka. In the FDA's patient guide, plasma is passed through two columns that contain dextran sulfate cellulose, a material that traps LDL cholesterol before the plasma goes back to the patient. The guide notes the system has been approved in the United States since 1996 for patients with very high LDL cholesterol who are not responding to diet and medical treatment.

It is a second-line option. Statins usually come first, but not all patients reach their LDL target with statins, and in those cases a physician may recommend apheresis.

Who is lipoprotein apheresis for?

Lipoprotein apheresis is for a small, criteria-defined group: mostly people with FH, an inherited cause of very high LDL, whose cholesterol stays dangerously high after diet and maximum tolerated drug therapy. The FDA approval for the Liposorber system defines that group by LDL levels.

The FDA-approved indications in PMA supplement P910018/S017, decided July 15, 2015, cover high-risk patients for whom diet has been ineffective and maximum drug therapy has been ineffective or not tolerated:

  • Functional homozygous hypercholesterolemia with LDL-C above 500 mg/dL
  • Functional heterozygous hypercholesterolemia with LDL-C of 300 mg/dL or more
  • Functional heterozygous hypercholesterolemia with LDL-C of 160 mg/dL or more and documented coronary heart disease

The Family Heart Foundation lists the people who can have it as people with FH, with or without cardiovascular disease, people with homozygous FH (HoFH, the form inherited from both parents), and people with high Lp(a) who also have FH and cardiovascular disease. It adds that children with HoFH can begin as early as 3 years old.

Can you get lipoprotein apheresis for high Lp(a) alone?

High Lp(a) on its own is not one of the listed groups in either source above. Family Heart lists high Lp(a) only together with FH and cardiovascular disease, and the 2015 indication update for the Liposorber, PMA supplement S017, is written entirely in LDL cholesterol terms and does not mention Lp(a). Device indications can change through later supplements, so the current label is worth confirming with the treating center.

If high Lp(a) is the main concern, these are useful questions for a lipid specialist:

  • Do I meet any device indication or insurer criteria, or only some of them?
  • Which apheresis system would the center use, and what is its current approved indication?
  • Would my insurer consider Lp(a) in a coverage decision, and what documentation would they need?

How is it different from plasma exchange and INUSpheresis?

Lipoprotein apheresis is selective: it removes LDL and Lp(a) from the plasma and returns that plasma. Therapeutic plasma exchange works differently. In the American College of Rheumatology's description, the patient's plasma is discarded and replaced with a substitute fluid from donors. INUSpheresis is a double-filtration method that filters plasma and returns it; this guide explains how plasma exchange and INUSpheresis differ.

The bigger difference is the evidence and the indication behind each.

Treatment What happens to plasma Defined use
Lipoprotein apheresis (e.g. Liposorber) Filtered through LDL-trapping columns, then returned FDA-approved for specific high-LDL groups
Therapeutic plasma exchange Discarded and replaced with substitute fluid Medical uses graded disease by disease by the American Society for Apheresis
Young-donor plasma infusion Donor plasma is infused FDA says plasma is not approved to treat normal aging or memory loss

An FDA approval covers a device for its stated indications. The Liposorber approval for severe high LDL does not extend to general wellness, aging or detox uses, whichever apheresis method a clinic uses. If you are weighing plasma exchange for a different reason, you can browse plasma exchange and apheresis clinics in Northvane's clinic finder.

How often is it done, and is it safe?

Lipoprotein apheresis is ongoing treatment, usually every week to every other week, because cholesterol levels climb back up after each session. The Family Heart Foundation calls it very safe and well tolerated by most people. The FDA patient guide gives more specific side effect figures and a list of people who should not have it.

Each session takes two to three hours, which can mean regular time away from work or school. People often eventually need a port or a fistula, a large blood vessel created by surgically joining a vein and an artery.

Side effects

The FDA patient guide lists low blood pressure, in 2.0 to 2.5% of treatments, as the most common adverse reaction. It also reports nausea and vomiting in 0.3 to 2.5% of treatments (1 in 333 to 1 in 40) and infection in 2 of 20 patients. These figures come from a small group of children treated with the system for high LDL, so they are a rough guide for adults rather than a precise rate.

Who should not have it

The same FDA guide lists as contraindications:

  • Taking an ACE inhibitor (a common blood pressure drug) that cannot be stopped for at least a day before each treatment
  • Being unable to receive anticoagulation (blood thinners)
  • Poor heart function, or a recent heart attack or stroke
  • Allergy to dextran sulfate cellulose, heparin or ethylene oxide

The ACE inhibitor rule matters in practice: Family Heart warns that the combination can lead to severe plummeting of blood pressure. Anyone considering treatment should review every medication with the treating team first.

Does Medicare or insurance cover lipoprotein apheresis, and what does it cost?

Medicare can cover lipoprotein apheresis for familial hypercholesterolemia, but regional contractors set the specific criteria, and private insurers set their own. National coverage determination 110.14 allows contractor discretion for therapeutic apheresis in refractory FH.

One example is Noridian, the Medicare contractor for Jurisdiction E, which includes California. Its coverage article A54543, in effect since October 1, 2015 and revised November 6, 2025, covers apheresis for FH that resists lifestyle changes plus maximal statins, with or without ezetimibe, in:

  • Functional homozygotes with LDL above 500 mg/dL
  • Functional heterozygotes without known cardiovascular disease and LDL above 300 mg/dL
  • Functional heterozygotes with known cardiovascular disease and LDL above 200 mg/dL
  • FH in pregnancy when the physician judges usual therapy inadequate to protect blood flow to the placenta

These thresholds do not match the device label exactly. For heterozygotes with heart disease, the 2015 FDA indication starts at 160 mg/dL, while Noridian's article sets the line above 200 mg/dL. A patient can fit one definition and not the other.

Because treatment repeats every one to two weeks, the figure that matters is your share per session multiplied over months. Ask the center and your plan for it in writing. This piece explains how insurance treats plasma exchange more broadly.

Questions to bring to the center and insurer:

  • Which coverage criteria apply to me, and do my lab results meet them?
  • Is prior authorization required, who submits it, and how long does it take?
  • What is the charge per session, and what will I pay after coverage?
  • Will I need a port or fistula, and is that covered separately?

Does lipoprotein apheresis help with anything besides cholesterol?

Outside severe high LDL, the evidence for lipoprotein apheresis is limited or absent. One kidney use has a narrow humanitarian authorization without proven effectiveness, and claims about removing environmental toxins come from a different apheresis method and are preliminary.

  • Established: LDL apheresis for FH that stays severe despite diet and maximum tolerated drugs. Researchers describe lipoprotein apheresis as highly effective and well-established for removing lipoproteins when conventional treatment fails.
  • Limited: The Liposorber is a Humanitarian Use Device for children with nephrotic syndrome caused by primary focal segmental glomerulosclerosis (FSGS), a kidney disease. The FDA states that the effectiveness of this device for this use has not been demonstrated. High Lp(a) without FH and heart disease sits outside the indications covered above.
  • Unproven: Detox uses. The same 2026 paper reports that the authors observed decreases in PFAS and micro- and nanoplastics after double filtration plasmapheresis, not lipoprotein apheresis as such, though responses varied across individuals and substances, and the authors say larger, well-designed clinical trials are needed. The paper does not address longevity. One author sits on the advisory board of Ayus Medical Group, and two others work there.

The evidence on plasma exchange and microplastics and on plasma exchange for longevity is covered separately. Approval to lower LDL in FH says nothing about either.

Common questions

Where is lipoprotein apheresis offered in the US?

There are about 60 lipoprotein apheresis centers in the United States, so some patients drive long distances. Family Heart publishes a state-by-state list of US and Canadian sites, including Mayo Clinic (Phoenix and Jacksonville), Cedars-Sinai, UC San Diego, UCSF, Emory, Vanderbilt and Northwell's North Shore University Hospital. The list also includes integrative clinics and is a directory, not a ranking.

How do apheresis guidelines grade lipoprotein apheresis?

The American Society for Apheresis grades apheresis disease by disease. Its 2026 Tenth Edition comprises 93 fact sheets and 183 graded and categorized indications. Ask your lipid specialist which category and grade apply to your specific diagnosis. Several committee members disclose consulting for apheresis manufacturers, and several also disclose research grants from device companies.

Sources8 cited
  1. [1]Lipoprotein Apheresis - Family Heart Foundation · familyheart.org
  2. [2]two columns that contain dextran sulfate cellulose · fda.gov
  3. [3]Premarket Approval (PMA) · accessdata.fda.gov
  4. [4]Plasma Exchange (Plasmapheresis) | American College of Rheumatology · rheumatology.org
  5. [5]American Society for Apheresis · doi.org
  6. [6]Important Information about Young Donor Plasma Infusions for Profit | FDA · fda.gov
  7. [7]Article - Therapeutic Apheresis for Familial Hypercholesterolemia (A54543) · cms.gov
  8. [8]highly effective and well-established · doi.org

For information, not medical advice. Suggest a correction · Editorial policy